RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer Clinical Trial

Official title:

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03189914
• Other study ID #: RX3117-003
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 2, 2017
• Est. completion date: November 21, 2019

Study information

• Verified date: November 2023
• Source: Processa Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.

Description:

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. The recommended phase 2 dose (RP2D) and schedule of RX-3117, in combination with Abraxane®, will be determined based on the safety profile, dose modification, and pharmacokinetics (PK). Phase 1 will be conducted using a combination of the single agent maximum tolerated dose (MTD) for RX-3117 and the Abraxane dose as per the package insert for patients with pancreatic cancer in combination with gemcitabine.

After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy. Approximately 10 subjects will participate in the Stage 1 at the dose identified in Phase 1 (RP2D). Subjects will be treated for up to 8 cycles of combined therapy. An interim analysis will be conducted after 10 evaluable subjects have been treated at the RP2D, have completed a minimum of 4 cycles of therapy, or have discontinued therapy due to progressive disease before completing 4 cycles. If an adequate number of Responders are observed out of the initial 10 evaluable subjects, then 40 additional subjects will be enrolled to participate in Stage 2. Subjects will be treated for up to 8 cycles of combined therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: November 21, 2019
• Est. primary completion date: October 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Disease Related

1. Subject has confirmed histologic or cytologic evidence of metastatic pancreatic cancer and has no prior treatment for metastatic pancreatic cancer.

2. Subject has measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

3. Subject has a life expectancy of at least 3 months.

4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

Demographic

5. Males or females = 18 years of age

6. Subject must be able to swallow capsules

7. Subject must have adequate venous access for intravenous (IV) infusion

Laboratory

8. Subject has hemoglobin = 9.0 g/dL at Screening

9. Subject has absolute neutrophil count (ANC) = 1.5 x 109/L at Screening

10. Subject has platelet count = 100 x 109/L at Screening

11. Subject has serum creatinine = 1.5 times the upper limit of normal (ULN) at Screening. Subjects with serum creatinine levels > 1.5 times the ULN must have a 24-hour urine creatinine clearance = 60 mL/min

12. Subject has serum bilirubin = 1.5 times the ULN (except in subjects with Gilbert's Syndrome who must have serum bilirubin < 3.0 x ULN)

13. Subject has aspartate aminotransferase (AST; SGOT) and alanine aminotransferase (ALT; SGPT) = 2.5 times the ULN (OR, AST and ALT = 5 times the ULN in the presence of known liver metastases)

14. Subject has alkaline phosphatase = 2.5 times the ULN (OR = 5 times the ULN in the presence of known liver or bone metastases)

15. Subject has normal coagulation parameters (prothrombin time [PT] and/or international normalized ratio [INR], and partial thromboplastin time [PTT] within normal limits [<1.2 x ULN])

16. Subject has potassium concentration within normal range, or correctable with supplements.

17. Oxygen saturation by pulse oximetry = 92% at rest.

18. For women of childbearing potential: Negative serum pregnancy test during screening and negative serum or urine pregnancy test at start of study therapy (Cycle1 Day 1).

Reproductive

19. For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the screening visit throughout the study treatment period and for 30 days following the last dose of study drug.

20. Female subjects of non-childbearing potential defined as having amenorrhea for at least 24 consecutive months, a documented hysterectomy, or a documented bilateral oophorectomy)

21. For fertile male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the start of study therapy throughout the study treatment period and for 30 days following the last dose of study drug and to refrain from sperm donation from the start of study treatment throughout the study treatment period and for 30 days following the last dose of study drug.

Ethical

22. In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.

23. Before any study-specific procedure, the appropriate written informed consent must be obtained

Exclusion Criteria:

Disease Related

1. Subject has primary brain tumors or clinical evidence of active brain metastasis

2. Subject has undergone major surgery within 4 weeks of the start of study treatment. Laparoscopy and central venous catheter placement are not considered major surgery

Medications

3. Subject has a history of systemic corticosteroid use within 7 days before Day 1 of Cycle 1

General

4. Subject has an active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy

5. Subject has uncontrolled diabetes as assessed by the investigator

6. Subject has a second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers treated with curative intent and no known active disease within 3 years before planned start of study therapy

7. Subject has an active infection of hepatitis B, hepatitis C or human immunodeficiency virus

8. Female subjects who are pregnant, planning a pregnancy or breast feeding during the study

9. Subject has a high cardiovascular risk, including, but not limited to, subjects with congestive heart failure (New York Heart Association [NYHA] Class III or IV), cardiac arrhythmia, unstable angina, coronary stenting or acute coronary syndromes within 6 months before planned start of study therapy or r myocardial infarction within one year before planned start of study therapy

10. Criterion removed

11. Subject has a history of prior allogeneic bone marrow progenitor cell or solid organ transplantation.

12. Subject has known acute or chronic pancreatitis.

13. Subject has persistent diarrhea, malabsorption, or known sub-acute bowel obstruction = NCI CTCAE Grade 2, despite medical management.

14. Subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery and bariatric surgery)

15. All acute toxic effects of any prior antitumor therapy resolved to Grade = 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or neurotoxicity [Grade 1 or 2 permitted], or anemia [Grade 2 permitted])

16. Subject has any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results

17. Subject has a history of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. Any lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity.

18. Subject is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.

19. Subject has a history of hypersensitivity to RX-3117, gemcitabine, azacytidine cytosine arabinoside, paclitaxel, nab-paclitaxel, or their excipients.

20. Subject is unwilling or unable to comply with study requirements or planned unavailability for follow-up assessments.

Related Conditions & MeSH terms

• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• RX-3117
RX-3117 will be administered orally in combination with Abraxane.

Locations

Country	Name	City	State
United States	Rexahn Site	Boston	Massachusetts
United States	Rexahn Site	Joliet	Illinois
United States	Rexahn Site	Lexington	Kentucky
United States	Rexahn Site	Milwaukee	Wisconsin
United States	Rexahn Site	New York	New York
United States	Rexahn Site	Skokie	Illinois
United States	Rexahn Site	Spartanburg	South Carolina
United States	Rexahn Site	Spokane	Washington
United States	Rexahn Site	Tucson	Arizona
United States	Rexahn Site	Weeki Wachee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Processa Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Measurement of Protein Biomarkers Related to RX-3117 or Pancreatic Cancer (Phase 1 and 2)		Baseline, and at 8, 6, 24, and 32 weeks
Other	Tumor Burden Response (Phase 2)	Changes in tumor burden response via tumor marker measurement	Baseline, and at 8, 6, 24, and 32 weeks
Other	Quality of Life (QOL) (Phase 1 and 2)	Weekly patient reported quality of life measures using validated QOL questionnaires	9 months
Primary	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)	Number of participants who experienced a treatment-related adverse event	9 months
Primary	Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)	Participants with adverse events coded using the MedDRA Dictionary (Version 20.0) to Investigations. Due to the underlying disease, not all abnormal labs are reported.	9 months
Primary	Number of Participants With Vital Sign Abnormalities (Phase 1 and 2)	Number of participants with clinically significant vital sign abnormalities (Phase 1 and 2) including heart rate, respiration rate, and blood pressure	9 months
Primary	Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)	Number of participants with clinically significant ECG abnormalities (Phase 1 and 2)	1 month
Primary	Number of Dose-limiting Toxicities (DLTs) (Phase 1)		4 weeks
Primary	Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)	Participants must have progression Free Survival (PFS) > 4 months or objective clinical response (complete or partial response).	9 months
Secondary	Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1		Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1		Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1		Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Overall Response Rate [ORR] (Phase 1 and Phase 2)	Overall Response Rate will be based on the RECIST v1.1 and is defined as the percentage of subjects meeting criteria of Complete Response (CR) or Partial Response (PR). CR or PR must be confirmed at least 4 weeks after the date of the original CR or PR.	Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Secondary	Time to Response [TTR] (Phase 1)		Up to 32 weeks
Secondary	Duration of Response [DOR] (Phase 1 and Phase 2)	Duration of response is defined as the time from documentation of response to disease progression.	Up to 32 weeks
Secondary	Progression-free Survival [PFS] (Phase 1)	Progression Free Survival defined as the percentage of subjects who are alive in the study and not in progression.	Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Secondary	Time to Progression (Phase 2)	Time to Progression defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression.	Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Secondary	Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Secondary	Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1		Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Secondary	Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Secondary	Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1		Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Secondary	Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Secondary	Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1		Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Secondary	Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15		Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)